Gemcitabine-Based Neoadjuvant Treatment in Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis of Individual Patient Data

2018 ◽  
Author(s):  
Francesco Giovinazzo ◽  
Fiammetta Soggiu ◽  
Chang Moo Kang ◽  
Mark Zalupski ◽  
Hasham Ahmad ◽  
...  
Keyword(s):  
Systematic Review ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Individual Patient Data ◽  
Meta Analysis ◽  
Neoadjuvant Treatment ◽  
Patient Data ◽  
Ductal Adenocarcinoma ◽  
Borderline Resectable

Sentinel Lymph Node Procedure in Colon Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data

2020 ◽  
Author(s):  
Marjolein Ankersmit ◽  
Martijn W. Heymans ◽  
Otto Hoekstra ◽  
Stijn L. Vlek ◽  
Linda J. Schoonmade ◽  
...  
Keyword(s):  
Systematic Review ◽  
Colon Cancer ◽  
Lymph Node ◽  
Sentinel Lymph Node ◽  
Individual Patient Data ◽  
Meta Analysis ◽  
Patient Data ◽  
Sentinel Lymph Node Procedure

scholarly journals Genome-wide copy number variations as molecular diagnostic tool for cutaneous intermediate melanocytic lesions: a systematic review and individual patient data meta-analysis

2021 ◽  
Author(s):  
Chiel F. Ebbelaar ◽  
Anne M. L. Jansen ◽  
Lourens T. Bloem ◽  
Willeke A. M. Blokx
Keyword(s):  
Systematic Review ◽  
Sensitivity And Specificity ◽  
Copy Number ◽  
Individual Patient Data ◽  
Meta Analysis ◽  
Copy Number Variations ◽  
Patient Data ◽  
Melanocytic Lesions ◽  
Genome Wide ◽  
Malignant Lesions

AbstractCutaneous intermediate melanocytic neoplasms with ambiguous histopathological features are diagnostically challenging. Ancillary cytogenetic techniques to detect genome-wide copy number variations (CNVs) might provide a valuable tool to allow accurate classification as benign (nevus) or malignant (melanoma). However, the CNV cut-off value to distinguish intermediate lesions from melanoma is not well defined. We performed a systematic review and individual patient data meta-analysis to evaluate the use of CNVs to classify intermediate melanocytic lesions. A total of 31 studies and 431 individual lesions were included. The CNV number in intermediate lesions (median 1, interquartile range [IQR] 0–2) was significantly higher (p<0.001) compared to that in benign lesions (median 0, IQR 0–1) and lower (p<0.001) compared to that in malignant lesions (median 6, IQR 4–11). The CNV number displayed excellent ability to differentiate between intermediate and malignant lesions (0.90, 95% CI 0.86–0.94, p<0.001). Two CNV cut-off points demonstrated a sensitivity and specificity higher than 80%. A cut-off of ≥3 CNVs corresponded to 85% sensitivity and 84% specificity, and a cut-off of ≥4 CNVs corresponded to 81% sensitivity and 91% specificity, respectively. This individual patient data meta-analysis provides a comprehensive overview of CNVs in cutaneous intermediate melanocytic lesions, based on the largest pooled cohort of ambiguous melanocytic neoplasms to date. Our meta-analysis suggests that a cut-off of ≥3 CNVs might represent the optimal trade-off between sensitivity and specificity in clinical practice to differentiate intermediate lesions from melanoma.

Sign in / Sign up

Export Citation Format

Share Document